BridgeBio Pharma Enters Material Definitive Agreement

TL;DR

BridgeBio just signed a big deal, filing an 8-K on 8/16.

AI Summary

BridgeBio Pharma, Inc. announced on August 16, 2024, that it has entered into a material definitive agreement. The company, incorporated in Delaware, filed an 8-K report detailing this agreement. Further specifics regarding the agreement's nature and financial implications are not detailed in the provided excerpt.

Why It Matters

This filing indicates a significant new contract or partnership for BridgeBio Pharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant financial or operational risks and rewards, but the details are not yet disclosed.

Key Players & Entities

• BridgeBio Pharma, Inc. (company) — Registrant
• August 16, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 3160 Porter Dr., Suite 250 Palo Alto, CA 94304 (address) — Principal executive offices
• (650) 391-9740 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BBIO The Nasdaq Global Se
• $300 million — s Complex. The Investors have committed $300 million of tranched financing to GondolaBio. Th

Filing Documents

• ef20034419_8k.htm (8-K) — 32KB
• ef20034419_ex10-1.htm (EX-10.1) — 489KB
• ef20034419_ex10-2.htm (EX-10.2) — 660KB
• 0001140361-24-037974.txt ( ) — 1542KB
• bbio-20240816.xsd (EX-101.SCH) — 4KB
• bbio-20240816_lab.xml (EX-101.LAB) — 21KB
• bbio-20240816_pre.xml (EX-101.PRE) — 16KB
• ef20034419_8k_htm.xml (XML) — 4KB

01

Item 1.01. Entry into a Material Definitive Agreement. On August 16, 2024, BridgeBio Pharma, Inc. (the "Company"), on the recommendation of a special committee of independent and disinterested directors of the Company, entered into a transaction agreement (the "Transaction Agreement") providing for the formation and funding by certain third party investors (the "Investors") of GondolaBio, LLC, a Delaware limited liability company ("GondolaBio"), as a joint venture for the purpose of researching, developing, manufacturing and commercializing pharmaceutical products, including those contributed to GondolaBio by the Company (the "Transaction"). The Investors providing financing to GondolaBio consist of an investor syndicate, including Viking Global Investors LP, Patient Square Capital, Sequoia Capital, Frazier Life Sciences, Cormorant Asset Management, Aisling Capital and an entity owned by Neil Kumar, the Company's Chief Executive Officer. The Transaction was consummated (the "Closing") on the date of signing the Transaction Agreement. Pursuant to the Transaction Agreement, the Company contributed to GondolaBio certain early-stage clinical and pre-clinical stage programs in the areas of Erythropoietic Protoporphyria, Alpha-1 Antitrypsin Deficiency, and Tuberous Sclerosis Complex. The Investors have committed $300 million of tranched financing to GondolaBio. The Company's initial interest in GondolaBio will be approximately 45% and will be subject to reduction as additional tranches of capital contributions are funded. Also on August 16, 2024, BridgeBio Pharma LLC, a wholly owned subsidiary of the Company, became a party to the Amended and Restated Limited Liability Company Agreement of GondolaBio (the "LLC Agreement"). The LLC Agreement sets forth, among other things, the economic and governance rights of the members of GondolaBio, including governance rights, economic preferences, privileges, restrictions and obligations of the members. The foregoing agreements

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 10.1 Transaction Agreement, dated as of August 16, 2024, by and among BridgeBio Pharma, Inc., Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown (Aggregator) LP, Patient Square Bravo Aggregator, LP, SC US/E GROWTH FUND X MANAGEMENT, L.P., SC US/E Venture Fund XVIII Management, L.P., Frazier Life Sciences XI, L.P., Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Cormorant Private Healthcare Fund IV, LP, Cormorant Private Healthcare Fund V, LP, Cormorant Global Healthcare Master Fund, LP, Aisling V Bridge Splitter LP, Kumar Haldea Revocable Trust and GondolaBio, LLC.* 10.2 Amended and Restated Limited Liability Company Agreement of GondolaBio, LLC, dated as of August 16, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BridgeBio Pharma, Inc. Date: August 20, 2024 By: /s/ Brian C. Stephenson Brian C. Stephenson, Ph.D., CFA Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR